Objective -To compare the potential cost effectiveness of vaccination against hepatitis B virus (HBV) targeted at genitourinary clinic (GU) Within Europe, universal vaccination was first adopted in the southern countries, where HBV is a far more serious problem than in northern regions. In the United Kingdom, however, a decision about implementing universal infant or adolescent immunisation is unlikely to be made solely on the grounds of WHO recommendations or as a result of the approaches adopted in other European countries. Rather it will be made on grounds of affordability, cost effectiveness in relation to other demands on the health services, and after determining whether the burden of disease and mortality induced by HBV in the UK is significant (both in its own right and relative to other causes of morbidity and mortality). Advocates of universal HBV immunisation in the UK must therefore argue their case taking due account ofthe issue ofthe cost effectiveness in the UK of the different programme options.78 In particular, it is important to provide quantitative details of the predicted effectiveness of universal infant (or adolescent) immunisation in comparison with nationally promoted selective immunisation programmes specifically targeted at individuals at risk, such as those who attend genitourinary (GU) clinics or intravenous drug user centres. For example, at present GU clinic vaccination is operated on a somewhat piecemeal basis with a good deal of variation in uptake and coverage between
Objective -To compare the potential cost effectiveness of vaccination against hepatitis B virus (HBV) targeted at genitourinary clinic (GU) attendees with that of universal infant vaccination. Design -A mathematical model of sexual and perinatal transmission of HBV was used to compare the effectiveness among heterosexual and homosexual populations of programmes ofmass infant vaccination and targeted immunisation of genitourinary medicine (GU) clinic attendees. Each was applied to 90% of the eligible population with differing assumptions about rates of compliance and seroconversion -problems of delivery (obtaining high compliance) was considered a significant drawback of targeted vaccination. Observed relationships between GU clinic attendance and sex partner change rates for heterosexuals and for homosexuals were used to define the rates of vaccination uptake within sexual activity risk groups. Setting -England and Wales. Results -Model results showed that for heterosexuals universal infant vaccination became more effective than clinic based vaccination only approximately 40 years after the start of the programme and that the predicted cost effectiveness of GU clinic vaccination was greater at all times. For homosexuals, clinic vaccination was always more effective over the time frame considered, but by 50 years if it were carried out without prior screening it had become appreciably less cost effective than a mass infant programme. With prior screening in GU clinics this cost effectiveness deficit was only marginal. Conclusions -Targeted vaccination might have a much greater potential than is realised at present, particularly if it were possible to improve compliance of clinic attendees. A fuller comparison between mass infant and targeted vaccination must await the specific inclusion in the model of other risk groups such as intravenous drug users. An important determinant of the relative merits of the two approaches is the relationship between rates of attendance and of changing sexual partners. Further research on this is required. Within Europe, universal vaccination was first adopted in the southern countries, where HBV is a far more serious problem than in northern regions. In the United Kingdom, however, a decision about implementing universal infant or adolescent immunisation is unlikely to be made solely on the grounds of WHO recommendations or as a result of the approaches adopted in other European countries. Rather it will be made on grounds of affordability, cost effectiveness in relation to other demands on the health services, and after determining whether the burden of disease and mortality induced by HBV in the UK is significant (both in its own right and relative to other causes of morbidity and mortality). Advocates of universal HBV immunisation in the UK must therefore argue their case taking due account ofthe issue ofthe cost effectiveness in the UK of the different programme options.78 In particular, it is important to provide quantitative details of the predicted effectiveness of universal infant (or adolescent) immunisation in comparison with nationally promoted selective immunisation programmes specifically targeted at individuals at risk, such as those who attend genitourinary (GU) clinics or intravenous drug user centres. For example, at present GU clinic vaccination is operated on a somewhat piecemeal basis with a good deal of variation in uptake and coverage between clinics9'0 and there may be much scope for increasing its impact by a uniformly applied policy of vaccinating all those who attend.
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In much work on cost effectiveness, it has become the practice to base analysis on epidemiological data derived from randomised controlled trials. However, in assessing the benefits of immunisation against an infectious disease it is insufficient to assume a constant risk of infection and to extrapolate the effect of vaccinating a relatively small group of trial participants in an attempt to predict the impact of a programme vaccinating a much larger proportion of the general population. To do so ignores the importance of the level of immunity in the population in controlling the spread of infectious disease. Immunisation of a group of individuals not only protects those individuals, but also reduces the risk or force of infection for people who are unvaccinated because the pool of potentially infectious individuals is now smaller. The impact on rates of infection of this "herd immunity effect"'1 changes nonlinearly as the overall proportion of the population which is vaccinated increases, and this undermines attempts to base predictions on linear extrapolation of results based on controlled randomised trials. An additional drawback of the traditional approach is seen when considering infections such as HBV where several decades may elapse between infection and the risk against which vaccination is primarily aimed -that is, severe chronic disease. In these circumstances, it becomes difficult to countenance delaying the implementation of a vaccination programme until trial results are known. Here we have avoided these drawbacks by adopting an alternative approach using a mathematical model which allows us to make projections of the impact of vaccination programmes over time, and which takes full account of the non-linearities that arise from the operation of herd immunity.
In in the data, and it is clear that more studies are needed to examine this variability. 
Results

RELATIONSHIP BETWEEN EFFECTIVENESS AND COST EFFECTIVENESS
Previous work8 showed that increasing the vaccination rate resulted in a less than pro rata increase in effectiveness and that cost effectiveness also became slightly poorer as the vaccination level increased (these measures were about an order of magnitude less for heterosexuals than for homosexuals). Here it is assumed that 90% of the eligible population receives the first dose of a schedule in each case. Figure 2 shows the relationship between the cost effectiveness ratio and effectiveness for policies of universal vaccination of infants and vaccination targeted at attendees of GU clinics at time points of 10, 25, and 50 years after the start of vaccination. For infant vaccination it was assumed that all those given the first dose went on to receive the remainder of the course and that 99% became immune.'4 For GU clinic attendees, ofthose receiving the first dose, 80% went on to receive the second dose and 60% the third (Gilson R, personal communication). Seroconversion rates for doses one, two, and three were set at 31%, 89%, and 99% respectively for heterosexuals, and 24%, 77%, and 92% respectively for homosexuals. '5 Figure 2(a) shows results for the heterosexual population; the cost effectiveness of targeted vaccination is clearly much greater at all time points than for infant vaccination. In terms of effectiveness, GU vaccination has more impact over 10 and 25 year time spans (deeper into the page), but effectiveness of infant vaccination increases markedly over the second 25 years. It is nearly 40 years since the start of vaccination, however, before its effectiveness exceeds that of GU clinic vaccination Figure 2 (b) shows a somewhat different picture for homosexuals. The lower portions ofthe light bars show the effect oftargeted vaccination without prior screening, assuming that 90% of individuals attending a GU clinic are vaccinated (unless vaccinated on a previous occasion with confirmation of a satisfactory vaccine response). In this case GU clinic vaccination is much more effective than universal infant vaccination at all time points as a continuing programme of infant vaccination will take several decades to With this need for better data in mind and having assumed plausible rates of compliance and seroconversion for each of the three doses, the model results suggest that vaccination targeted at homosexuals attending GU clinics could be highly effective in stemming HBV factor identified, numbers of unreported asymptomatic infections are likely to be significant,20 and the level of misdiagnosis is unknown (it has been observed that in many cases symptoms can easily be mistaken for those of glandular fever for example21).
As was noted earlier and in Williams et al,8 a high proportion of homosexuals attend GU clinics relatively regularly. Targeted vaccination is somewhat less effective for heterosexuals because of their comparatively low rate of attendance at GU clinics, but nevertheless it still takes nearly 50 years for its effectiveness to be exceeded by mass immunisation of infants.
Over the longer term (>50 years) the effectiveness of mass infant vaccination is much greater than that of targeted vaccination because of low rates of clinic attendance by heterosexuals. Because delivery occurs across all ages for GU programmes and because of the time it takes for vaccinated infants to reach a sexually active age (an argument in favour of vaccination in adolescence) vaccination in GU clinics will show its benefits earlier. However, our analyses suggest that the long term potential of targeted vaccination approaches that of infant vaccination, for the homosexual population at least. It may even be greater given present uncertainties regarding data. (fig 2(a) ). With screening before vaccination in GU clinics, clinic vaccination of homosexuals is also much more cost effective at 10 and 25 years and values of the cost effectiveness measure for infant and homosexual vaccination policies are broadly similar at 50 years (fig 2(b) ).
Although better data are clearly needed, the strength of this modelling approach lies in the ease with which fresh projections can be carried out as and when improved data become available. It is also a very straightforward matter to test how sensitive the results of a vaccination programme are to variations in, for example, level of uptake22 or changes in vaccine cost, by simply varying the appropriate input (using a more sophisticated but still straightforward sensitivity analysis,23 interactions between parameters can also be explored). We have used cost estimates based on UK conditions, but our model framework makes it a simple matter to provide revised projections relevant to other countries, given appropriate costings and parameter estimates. Although the cost of vaccine in many countries, including the UK, is such that effects of differences in delivery costs are likely to be small by comparison, the implementation of mass infant vaccination programmes occasions opportunities for negotiating price reductions for bulk supply in markets where the advent of a number of new recombinant HBV vaccines provides the potential for increased price competition between suppliers.
In conclusion, the view is often expressed that vaccination targeted at high risk groups has failed to reduce the HBV incidence. It should be borne in mind that HBV vaccination began only in the early 1 980s so that any measure of impact can be based on little more than a decade of transmission. The work reported here and in Williams et al shows that the long duration ofthe carrier infectious period of HBV means it will be many years before any vaccination policy which is not aimed universally at all age groups has a major effect, and decades before its full impact is clear (underlining the importance of being clear about the time scale of an assessment of cost effectiveness). Moreover this work starts from the conservative assumption that incidence of new infection was at equilibrium prior to the start of vaccination. If incidence were actually increasing (for example, see data from the USA24) when vaccination was introduced it would take many years of vaccination before the incidence started to decline at all. In the meantime changes in behaviour as a result of the AIDS epidemic, particularly amongst 
